News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
285,092 Results
Type
Article (14937)
Company Profile (303)
Press Release (269847)
Multimedia
Podcasts (73)
Webinars (11)
Section
Business (81064)
Career Advice (160)
Deals (13592)
Drug Delivery (38)
Drug Development (51375)
Employer Resources (31)
FDA (5976)
Job Trends (5307)
News (147455)
Policy (10299)
Tag
Academia (930)
Accelerated approval (18)
Adcomms (14)
Allergies (76)
Alliances (22008)
ALS (122)
Alzheimer's disease (1022)
Antibody-drug conjugate (ADC) (219)
Approvals (6166)
Artificial intelligence (236)
Autoimmune disease (94)
Automation (9)
Bankruptcy (107)
Best Places to Work (4700)
BIOSECURE Act (6)
Biosimilars (99)
Biotechnology (231)
Bladder cancer (94)
Brain cancer (42)
Breast cancer (328)
Cancer (2989)
Cardiovascular disease (229)
Career advice (146)
Career pathing (6)
CAR-T (210)
CDC (5)
Cell therapy (542)
Cervical cancer (14)
Clinical research (44048)
Collaboration (1025)
Company closure (2)
Compensation (558)
Complete response letters (33)
COVID-19 (1098)
CRISPR (81)
C-suite (479)
Cystic fibrosis (108)
Data (4110)
Denatured (14)
Depression (80)
Diabetes (239)
Diagnostics (1434)
Digital health (11)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (171)
Drug pricing (42)
Drug shortages (3)
Duchenne muscular dystrophy (203)
Earnings (32415)
Editorial (23)
Employer branding (4)
Employer resources (29)
Events (52398)
Executive appointments (610)
FDA (7603)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (6)
Frontotemporal dementia (19)
Funding (912)
Gene editing (169)
Generative AI (18)
Gene therapy (459)
GLP-1 (486)
Government (1156)
Grass and pollen (3)
Guidances (173)
Healthcare (6747)
HIV (17)
Huntington's disease (38)
IgA nephropathy (68)
Immunology and inflammation (180)
Immuno-oncology (28)
Indications (53)
Infectious disease (1200)
Inflammatory bowel disease (152)
Inflation Reduction Act (10)
Influenza (37)
Intellectual property (152)
Interviews (18)
IPO (7471)
IRA (12)
Job creations (878)
Job search strategy (130)
Kidney cancer (9)
Labor market (22)
Layoffs (242)
Leadership (9)
Legal (1419)
Liver cancer (40)
Longevity (9)
Lung cancer (422)
Lymphoma (245)
Machine learning (21)
Management (7)
Manufacturing (339)
MASH (127)
Medical device (2786)
Medtech (2793)
Mergers & acquisitions (6703)
Metabolic disorders (671)
Multiple sclerosis (94)
NASH (13)
Neurodegenerative disease (208)
Neuropsychiatric disorders (63)
Neuroscience (1865)
NextGen: Class of 2025 (2082)
Non-profit (874)
Now hiring (28)
Obesity (297)
Opinion (122)
Ovarian cancer (126)
Pain (91)
Pancreatic cancer (143)
Parkinson's disease (211)
Partnered (13)
Patents (279)
Patient recruitment (288)
Peanut (42)
People (26732)
Pharmaceutical (47)
Pharmacy benefit managers (6)
Phase I (15523)
Phase II (20389)
Phase III (13044)
Pipeline (2627)
Policy (86)
Postmarket research (879)
Preclinical (6563)
Press Release (30)
Prostate cancer (138)
Psychedelics (48)
Radiopharmaceuticals (232)
Rare diseases (582)
Real estate (1473)
Recruiting (12)
Regulatory (9917)
Reports (19)
Research institute (975)
Resumes & cover letters (18)
Rett syndrome (21)
RNA editing (16)
RSV (17)
Schizophrenia (116)
Series A (169)
Series B (122)
Service/supplier (1)
Sickle cell disease (75)
Special edition (17)
Spinal muscular atrophy (118)
Sponsored (17)
Startups (2015)
State (1)
Stomach cancer (5)
Supply chain (31)
Tariffs (17)
The Weekly (58)
Vaccines (324)
Venture capital (58)
Weight loss (161)
Women's health (23)
Worklife (2)
Date
Last 7 days (60)
Last 30 days (1278)
Last 365 days (18448)
2025 (18449)
2024 (20911)
2023 (22786)
2022 (27315)
2021 (28175)
2020 (23750)
2019 (16600)
2018 (11998)
2017 (13966)
2016 (12079)
2015 (14683)
2014 (10579)
2013 (7614)
2012 (7698)
2011 (7787)
2010 (7572)
Location
Africa (154)
Alabama (63)
Alaska (2)
Arizona (89)
Arkansas (5)
Asia (18638)
Australia (3148)
California (6789)
Canada (1786)
China (721)
Colorado (232)
Connecticut (255)
Delaware (223)
Europe (39481)
Florida (868)
Georgia (202)
Hawaii (2)
Idaho (17)
Illinois (375)
India (31)
Indiana (165)
Iowa (8)
Japan (212)
Kansas (79)
Kentucky (12)
Louisiana (8)
Maine (11)
Maryland (715)
Massachusetts (5306)
Michigan (107)
Minnesota (253)
Mississippi (3)
Missouri (36)
Montana (15)
Nebraska (5)
Nevada (30)
New Hampshire (18)
New Jersey (1623)
New Mexico (12)
New York (1712)
North Carolina (793)
North Dakota (6)
Northern California (3300)
Ohio (170)
Oklahoma (11)
Oregon (22)
Pennsylvania (1224)
Puerto Rico (8)
Rhode Island (26)
South America (215)
South Carolina (9)
Southern California (2673)
Tennessee (40)
Texas (902)
United States (22536)
Utah (97)
Virginia (132)
Washington D.C. (36)
Washington State (562)
West Virginia (1)
Wisconsin (37)
285,092 Results for "tp therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
October 27, 2025
·
9 min read
Press Releases
Health Canada Approves MedMira’s Reveal(R) Rapid TP Test - Urgent New Tool In The Battle Against Syphilis
August 26, 2025
·
5 min read
Press Releases
PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
September 10, 2025
·
9 min read
Press Releases
Sumitomo Pharma America Announces that the European Medicines Agency Has Granted Orphan Drug Designation to Nuvisertib (TP-3654) for the Treatment of Myelofibrosis
July 30, 2025
·
4 min read
Press Releases
Sumitomo Pharma America Announces that Nuvisertib (TP-3654) Has Received FDA Fast Track Designation for the Treatment of Myelofibrosis
June 13, 2025
·
5 min read
Press Releases
SELLAS Unveils Breakthrough Preclinical Data Highlighting Efficacy of SLS009 in TP53 Mutated AML at the 2025 AACR Conference
April 28, 2025
·
6 min read
Press Releases
Thetis Pharmaceuticals Presents New Preclinical and Clinical Data for TP-317 at ECCO 2025
February 19, 2025
·
3 min read
Genetown
Karyopharm Presents Updated Exploratory Subgroup Analyses from SIENDO Study in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer During 2024 ASCO Plenary Series: Rapid Abstract Updates
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced the presentation of updated exploratory subgroup analyses from the SIENDO study, in patients with advanced or recurrent TP53 wild-type endometrial cancer at the 2024 American Society of Clinical Oncology Annual Meeting.
June 1, 2024
·
17 min read
Drug Development
Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) AML Patients at the EHA 2024 Congress
Shattuck Labs, Inc., a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, announced the presentation of additional data from the Phase 1B dose expansion clinical trial of SL-172154 with AZA in frontline HR-MDS and TP53m AML patients.
May 14, 2024
·
7 min read
Genetown
Affini-T Therapeutics to Present Data From Its Preclinical Programs Targeting KRAS G12D and TP53 R175H at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting
Affini-T Therapeutics, Inc. today announced that data from its preclinical gene edited HLA-A*11:01 KRAS G12D (AFNT-212) and HLA-A*02:01 TP53 R175H T Cell Receptor (TCR) T cell therapy products for the treatment of solid cancers will be presented at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting held in Baltimore, MD May 7-11.
May 1, 2024
·
3 min read
1 of 28,510
Next
